(No ratings)
Dr. Jack Meng-Fen Su, MD is a pediatric oncologist in Pasadena, TX specializing in pediatric oncology. He graduated from University of California, San Francisco (UCSF), School of Medicine. Dr. Jack Meng-Fen Su, MD is affiliated with Baylor College of Medicine and Texas Children's.
Dr. Jack Meng-Fen Su, MD graduated from University of California, San Francisco (UCSF), School of Medicine. He completed residency at University of California, San Francisco (UCSF) Affiliated Hospitals. He is certified by the California Licensure of Physicians and Surgeons, Medical Board of California and has a state license in Texas.
Medical School: University of California, San Francisco (UCSF), School of Medicine
Residency: University of California, San Francisco (UCSF) Affiliated Hospitals
Board Certification: California Licensure of Physicians and Surgeons, Medical Board of California (2016)
Licensed In: Texas
Dr. Jack Meng-Fen Su, MD is associated with these hospitals and organizations:
Dr. Jack Meng-Fen Su, MD does not have any reviews yet, be the first to leave a review of Dr. Jack Meng-Fen Su, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Jack Meng-Fen Su, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| GlaxoSmithKline, LLC. |
$610
MEKINIST $455 |
PROMACTA $85 |
ARZERRA $70 |
|---|---|---|---|
| GENZYME CORPORATION |
$375
ALPROLIX $375 |
||
| Baxter Healthcare |
$350
IPS - Liquid Premix $350 |
| Consulting Fee | $960 |
|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $375 |
Dr. Jack Su practices pediatric hematology/oncology in Houston, TX and Pasadena, TX. His hospital/clinic affiliations include Texas Children's and Baylor College of Medicine. Dr. Su's education and training includes medical school at the University of California, San Francisco (UCSF), School of Medicine and residency at a hospital affiliated with the University of California, San Francisco (UCSF). Awards and/or distinctions he has received include Study Chair, A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose); trial completed accrual, Pediatric Brain Tumor Consortium; and Co-Chair, New Agent. Dr. Su speaks Chinese.